Successful Treatment with Secukinumab in an Erythrodermic Psoriasis Patient with End-Stage Kidney Disease on Hemodialysis: A Case Report

Patients with erythrodermic psoriasis (EP) complicated by end-stage renal disease (ESRD) requiring hemodialysis are extremely rare in clinical practice, and treatment options for this specific population remain highly limited. Herein we report a case of an EP patient with ESRD, in whom treatment with an interleukin-17 (IL-17) inhibitor secukinumab not only rapidly alleviated erythrodermic symptoms but also resulted in a certain degree of improvement in renal function. At the 7-month follow-up, the patient maintained skin lesion clearance with no deterioration in renal function-a finding that has not been consistently documented in previous literature. This case suggests that for patients with psoriasis complicated by kidney disease IL-17 inhibitors may serve as a potentially favorable therapeutic option.

Authors

Institutions

Publication Details

Journal
Clinical Cosmetic and Investigational Dermatology
Published
2025-10-01
DOI
https://doi.org/10.2147/ccid.s545123
Citations
1
Primary Topic
Autoimmune Bullous Skin Diseases
Type
article
Field-Weighted Citation Impact
1.47

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Successful Treatment with Secukinumab in an Erythrodermic Psoriasis Patient with End-Stage Kidney Disease on Hemodialysis: A Case Report

Ruiqun Qi, Minghuan He, Li-Li Zhu, Xiaodong Sun et al.
1 citations
Clinical Cosmetic and Investigational Dermatology
Autoimmune Bullous Skin Diseases
1.47
article

Successful Treatment with Secukinumab in an Erythrodermic Psoriasis Patient with End-Stage Kidney Disease on Hemodialysis: A Case Report

Ruiqun Qi, Minghuan He, Li-Li Zhu, Xiaodong Sun, Xing‐Hua Gao, Song Guo Zheng, Panpan Liu, Sitong Liu, Shixuan Zhang
article en
1 citations

Abstract

Patients with erythrodermic psoriasis (EP) complicated by end-stage renal disease (ESRD) requiring hemodialysis are extremely rare in clinical practice, and treatment options for this specific population remain highly limited. Herein we report a case of an EP patient with ESRD, in whom treatment with an interleukin-17 (IL-17) inhibitor secukinumab not only rapidly alleviated erythrodermic symptoms but also resulted in a certain degree of improvement in renal function. At the 7-month follow-up, the patient maintained skin lesion clearance with no deterioration in renal function-a finding that has not been consistently documented in previous literature. This case suggests that for patients with psoriasis complicated by kidney disease IL-17 inhibitors may serve as a potentially favorable therapeutic option.

Clinical Cosmetic and Investigational DermatologyVol. Volume 18
National Health and Family Planning Commission (CN), Liaoning Provincial People's Hospital (CN), First Hospital of China Medical University (CN), China Medical University (CN)
National Natural Science Foundation of China, Natural Science Foundation of Liaoning Province
Openalex Percentile: Top 14%
Autoimmune Bullous Skin Diseases
1.47
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Successful Treatment with Secukinumab in an Erythrodermic Psoriasis Patient with End-Stage Kidney Disease on Hemodialysis: A Case Report — Ruiqun Qi, Minghuan He, et al. · Clinical Cosmetic and Investigational Dermatology (2025) | TGRS Research Map | TGRS